Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Jubilant Pharma Plans to Acquire Pharma Business in US 14
Partnerships 15
Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 15
Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 16
Jubilant Chemsys Enters into Research Agreement with Infectious Disease Research Institute 17
Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 18
Jubilant BioSys Enters Into Co-Development Agreement With Mnemosyne Pharma 19
Licensing Agreements 20
Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20
TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 21
Equity Offering 22
Jubilant Pharma Plans to Raise up to USD700 Million in IPO of Shares 22
Debt Offering 23
Jubilant Life Sciences Raises USD14 Million in Private Placement of 9.1% Debentures Due 2021 23
Jubilant Life Sciences Raises USD14 Million in Private Placement of 8.95% Debentures Due 2020 24
Jubilant Life Sciences Raises USD21 Million in Private Placement of 9.26% Debentures Due 2022 25
Jubilant Life Sciences Raises USD72.6 Million in Private Placement of Debentures 26
Jubilant Pharma Raises USD300 Million in Private Placement of 4.875% Bonds Due 2021 27
Jubilant Life Sciences Plans Debt Offering For US$250 Million 28
Asset Transactions 29
Narayana Health Acquires Hospital Business From Jubilant First Trust Healthcare 29
Acquisition 30
Drug Discovery and Development Solutions to Acquire Jubilant Discovery Services for USD2.9 Million 30
General Atlantic Divests its 6% Stake in Jubilant Life Sciences for USD2.2 Million 31
Jubilant Acquires Remaining 17.6% Stake in Cadista for up to USD33.2 Million in Tender Offer 32
Jubilant Life Sciences Ltd – Key Competitors 33
Jubilant Life Sciences Ltd – Key Employees 34
Jubilant Life Sciences Ltd – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 38
Financial Announcements 38
Oct 22, 2018: Jubilant Life Sciences: Q2 & H1 ‘FY19 Results 38
Jul 27, 2018: Jubilant Life Sciences- Q1 FY 2019 Results – Jubilant Reports Strong Performance in Q1’FY19 Revenue at Rs. 2,079 Crore, up 34% YoY 42
May 09, 2018: Jubilant Life Sciences – Q4/ FY2018 Results- Jubilant Reports Strong Performance in Q4’FY18 Revenue at Rs. 2,252 crore, up 41% YOY; EBITDA at Rs. 481 crore, up 52% YOY PAT at Rs 155 crore 45
Jan 17, 2018: Jubilant Reports Record Performance In Q3 FY2018; Highest Ever Revenues And Profits Revenue At Rs. 2,068 Crore, Up 42% YOY and Ebitda at Rs. 431 Crore, Up 28% YOY Pat At Rs. 213 Crore, Up 78% YOY With 49
Oct 28, 2017: Jubilant Life Sciences: Q2/H1 FY2018 Results 53
Jul 18, 2017: Jubilant Life Sciences: Q1 FY2018 Result 57
Jul 18, 2017: Jubilant Reports Q1 FY2018 Revenue of Rs. 1,596 Crore, UP 10% YOY Pharma Segment Records Highest Ever Sales Ebitda of Rs. 344 Crore and Margins of 21.6%; Pat of Rs. 147 Crore 59
May 23, 2017: Jubilant Life Sciences Reports Total RevenueOf INR26.2 Billion In Fiscal 2017 61
Feb 07, 2017: Jubilant Reports Strong Performance In Q3 FY17; Sales At Rs. 1,492 Crore, Up By 7% YOY EBITDA At Rs. 337 Crore; Up 9% YOY With Margins Of 22.6%; PAT At Rs. 120 Crore 62
Corporate Communications 65
Oct 22, 2018: Jubilant Life Sciences announces appointment of directors 65
Jan 17, 2018: Jubilant Life Sciences: Changes in the Board of Directors 66
Legal and Regulatory 67
Mar 04, 2018: Jubilant Life Sciences: Commissioner of State Excise Cancelled License DS-1 License and Form-I License relating to the Distillery operations 67
Jan 25, 2017: Jubilant Life Sciences is now Responsible Care 14001: 2013 certified 68
Other Significant Developments 69
Jun 01, 2017: Jubilant Life Sciences Provides Update on Gajraula Manufacturing Unit 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Jubilant Life Sciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Jubilant Pharma Plans to Acquire Pharma Business in US 14
Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 15
Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 16
Jubilant Chemsys Enters into Research Agreement with Infectious Disease Research Institute 17
Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 18
Jubilant BioSys Enters Into Co-Development Agreement With Mnemosyne Pharma 19
Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20
TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 21
Jubilant Pharma Plans to Raise up to USD700 Million in IPO of Shares 22
Jubilant Life Sciences Raises USD14 Million in Private Placement of 9.1% Debentures Due 2021 23
Jubilant Life Sciences Raises USD14 Million in Private Placement of 8.95% Debentures Due 2020 24
Jubilant Life Sciences Raises USD21 Million in Private Placement of 9.26% Debentures Due 2022 25
Jubilant Life Sciences Raises USD72.6 Million in Private Placement of Debentures 26
Jubilant Pharma Raises USD300 Million in Private Placement of 4.875% Bonds Due 2021 27
Jubilant Life Sciences Plans Debt Offering For US$250 Million 28
Narayana Health Acquires Hospital Business From Jubilant First Trust Healthcare 29
Drug Discovery and Development Solutions to Acquire Jubilant Discovery Services for USD2.9 Million 30
General Atlantic Divests its 6% Stake in Jubilant Life Sciences for USD2.2 Million 31
Jubilant Acquires Remaining 17.6% Stake in Cadista for up to USD33.2 Million in Tender Offer 32
Jubilant Life Sciences Ltd, Key Competitors 33
Jubilant Life Sciences Ltd, Key Employees 34
Jubilant Life Sciences Ltd, Other Locations 35
Jubilant Life Sciences Ltd, Subsidiaries 35
List of Figures
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11